Avadel Pharmaceuticals (AVDL) EPS (Weighted Average and Diluted) (2016 - 2020)
Historic EPS (Weighted Average and Diluted) for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q4 2020 value amounting to -$0.04.
- Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) rose 9652.15% to -$0.04 in Q4 2020 from the same period last year, while for Dec 2020 it was $0.12, marking a year-over-year increase of 10579.25%. This contributed to the annual value of -$0.12 for FY2020, which is 9434.09% up from last year.
- Per Avadel Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.04 for Q4 2020, which was up 9652.15% from -$0.2 recorded in Q3 2020.
- In the past 5 years, Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $0.68 during Q2 2017, and its lowest value of -$1.71 during Q4 2018.
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.2, with a median of -$0.2 in 2020.
- As far as peak fluctuations go, Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) surged by 50666.67% in 2017, and later plummeted by 76619.95% in 2018.
- Over the past 5 years, Avadel Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at $0.11 in 2016, then tumbled by 272.01% to -$0.2 in 2017, then crashed by 766.2% to -$1.71 in 2018, then rose by 28.8% to -$1.22 in 2019, then skyrocketed by 96.52% to -$0.04 in 2020.
- Its EPS (Weighted Average and Diluted) stands at -$0.04 for Q4 2020, versus -$0.2 for Q3 2020 and $0.44 for Q2 2020.